Peptide questions · Orforglipron
How long does orforglipron take to work?
Reviewed Evidence: EstablishedPublished by PepVault
Orforglipron’s onset is days–2 weeks, its peak effect comes at 72 weeks (trial endpoint), and its typical duration is ongoing, by the library’s timeline (backed by clinical trial data).
The timeline’s basis: FDA Foundayo label (DailyMed, effective July 2026); phase 3 ATTAIN-1 and -2, ATTAIN-MAINTAIN, ACHIEVE-1, -3 and -4. The label strengths differ from the trial doses (new tablet formulation).
Orforglipron week by week
The library places six of its research notes on orforglipron on the days they cover, from day 1 to day 60 and on: 6 on randomized trials.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–30 (weeks 1–5) | The 0.8 mg start | Randomized trial |
| Days 31–60 (weeks 5–9) | 2.5 mg, the second step | Randomized trial |
| From day 61 on | 5.5 mg, the first maintenance dose | Randomized trial |
| From day 91 on | 9 mg, an optional step | Randomized trial |
| From day 121 on | 14.5 mg, the step before the top | Randomized trial |
| From day 151 on | 17.2 mg, the top dose | Randomized trial |

Model. Individual results vary.
The orforglipron timeline’s milestones
The library’s timeline for orforglipron marks 7 points from week 1 to week 72, backed by clinical trial data overall.
- Week 1: Commonly reported: appetite dipping in the first days, with some nausea for a few
- Week 2: Steady drug levels arrive after about a week of daily tablets (label)
- Week 5: The label's step from 0.8 to 2.5 mg, after at least 30 days on the start dose
- Week 9: The label's step to 5.5 mg, the first dose it treats as a possible maintenance dose
- Week 13: Further steps to 9, 14.5 and 17.2 mg come only after 30 days or more on a dose, by response and tolerability
- Week 26: Commonly reported: the daily tablet becomes routine, with GI side effects quieter than during the climb
- Week 72: Where the ATTAIN weight trials read out
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why orforglipron takes that long
Orforglipron’s half-life is about 1.2–2 days (29–49 hours), so one dose is about 96.9% cleared after 6–10 days.
On its schedule (Daily) the doses overlap, and the level of orforglipron keeps climbing for about 4.8–10 days before it levels off, so the first 4.8–10 days run below the level the later weeks hold.
The notes on orforglipron follow the trials’ dose steps, 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg and 17.2mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
Orforglipron against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 21 metabolic & GLP-1 compounds, orforglipron among them; 15 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
Questions people ask
How long does orforglipron take to work?
Orforglipron’s onset is days–2 weeks, its peak effect comes at 72 weeks (trial endpoint), and its typical duration is ongoing, by the library’s timeline (backed by clinical trial data).
When does orforglipron reach its peak effect?
By the library’s timeline, orforglipron’s peak effect comes at 72 weeks (trial endpoint), backed by clinical trial data.
How long is orforglipron usually run?
The library’s timeline gives orforglipron’s typical duration as ongoing; its cycle note says: FDA-approved for long-term use alongside diet and activity.
What does the library say about the first days on orforglipron?
Its first note on orforglipron, for days 1–30 (weeks 1–5), is “The 0.8 mg start”, resting on randomized trials.